EUVIMEDEUVIMED entdecken
Crossref

Structure-Based Design of a Novel Covalent 4-(1-Methylindol-3-yl)pyrimidin-2-amine Series Targeting FGFR2 Resistance Mutations

Robert L Hudkins iD, Eric Allen, Samhita Iyer, Alexandra Balcer, Melissa Neal, Qing Ye, Marc Rideout, Caleb B Frye, Kirk J Nelson iD, Isaac D Hoffman iD, Jacqueline H Starrett, Todd Harris und 2 weitere

Journal of Medicinal Chemistry · 09.04.2026 · 69 (7) · 8614-8627

DOI: 10.1021/acs.jmedchem.6c00514 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 31.03.2026. Verfasst von Robert L Hudkins und 13 weiteren Autor:innen. Beteiligte Einrichtung: Tyra Biosciences, Inc., 2656 State Street, Carlsbad, California 92008, United States. Hauptthemen laut MEDLINE: Receptor, Fibroblast Growth Factor, Type 2, Pyrimidines, Drug Design, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Tyra Biosciences, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Fibroblast Growth Factor, Type 2PyrimidinesDrug DesignDrug Resistance, NeoplasmProtein Kinase InhibitorsAntineoplastic AgentsIndolesHumansAnimalsMutationStructure-Activity RelationshipMiceCell Line, Tumor

Substanzen

Receptor, Fibroblast Growth Factor, Type 2PyrimidinesFGFR2 protein, humanProtein Kinase InhibitorsAntineoplastic AgentsIndoles

Autor:innen und Institutionen

  • Tyra Biosciences, Inc., 2656 State Street, Carlsbad, California 92008, United States.

ORCID-Profile: Robert L Hudkins, Kirk J Nelson, Isaac D Hoffman

Förderung

  • Tyra Biosciences, Inc.

Zitieren

APA

Hudkins, R. L., Allen, E., Iyer, S., Balcer, A., Neal, M., Ye, Q., Rideout, M., Frye, C. B., Nelson, K. J., Hoffman, I. D., Starrett, J. H., Harris, T., Swanson, R. V., & Bensen, D. C. (2026). Structure-Based Design of a Novel Covalent 4-(1-Methylindol-3-yl)pyrimidin-2-amine Series Targeting FGFR2 Resistance Mutations. Journal of Medicinal Chemistry, 69(7), 8614-8627. https://doi.org/10.1021/acs.jmedchem.6c00514

Vancouver

Hudkins RL, Allen E, Iyer S, Balcer A, Neal M, Ye Q, et al. Structure-Based Design of a Novel Covalent 4-(1-Methylindol-3-yl)pyrimidin-2-amine Series Targeting FGFR2 Resistance Mutations. Journal of Medicinal Chemistry. 2026;69(7):8614-8627. doi:10.1021/acs.jmedchem.6c00514

BibTeX
@article{Hudkins2026,
  author = {Hudkins, Robert L and Allen, Eric and Iyer, Samhita and Balcer, Alexandra and Neal, Melissa and Ye, Qing and Rideout, Marc and Frye, Caleb B and Nelson, Kirk J and Hoffman, Isaac D and Starrett, Jacqueline H and Harris, Todd and Swanson, Ronald V and Bensen, Daniel C},
  title = {Structure-Based Design of a Novel Covalent 4-(1-Methylindol-3-yl)pyrimidin-2-amine Series Targeting FGFR2 Resistance Mutations},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {7},
  pages = {8614--8627},
  doi = {10.1021/acs.jmedchem.6c00514}
}
Kostenlos starten →